Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TELA Bio Inc TELA

Healthcare Medical Instruments & Supplies
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall... see more

Recent & Breaking News (NDAQ:TELA)

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

GlobeNewswire September 13, 2021

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021

GlobeNewswire August 16, 2021

TELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand

GlobeNewswire August 11, 2021

TELA Bio to Participate in Canaccord Genuity's 41st Annual Growth Conference

GlobeNewswire August 3, 2021

TELA Bio to Announce Second Quarter 2021 Financial Results

GlobeNewswire July 28, 2021

NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue Matrix

GlobeNewswire July 21, 2021

TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

GlobeNewswire June 14, 2021

TELA Bio Announces Changes to its Board of Directors

GlobeNewswire June 2, 2021

TELA Bio Names Marissa Conrad as Vice President of Clinical and Regulatory Affairs

GlobeNewswire May 25, 2021

TELA Bio to Participate in Upcoming Investor Conferences

GlobeNewswire May 21, 2021

TELA Bio Initiates BRAVO II Study of OviTex® for the Robotic Repair of Ventral Hernias

GlobeNewswire May 19, 2021

TELA Bio Announces First Quarter 2021 Financial Results

GlobeNewswire May 13, 2021

TELA Bio to Announce First Quarter 2021 Financial Results

GlobeNewswire April 29, 2021

TELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire March 24, 2021

TELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

GlobeNewswire March 18, 2021

TELA Bio to Report Fourth Quarter and Full Year 2020 Financial Results on March 24, 2021

GlobeNewswire March 2, 2021

TELA Bio to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

GlobeNewswire February 4, 2021

TELA Bio Reports Preliminary Results for Fourth Quarter and Full Year 2020

GlobeNewswire January 14, 2021

TELA Bio to Participate in Upcoming Needham Virtual Growth Conference

GlobeNewswire January 6, 2021

TELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development

GlobeNewswire January 5, 2021